Tumor Microenvironment of Esophageal Cancer.
Lars M SchiffmannPatrick Sven PlumHans F FuchsBenjamin BabicChristiane J BrunsThomas SchmidtPublished in: Cancers (2021)
Esophageal cancer is among the top ten most deadly cancers worldwide with adenocarcinomas of the esophagus showing increasing incidences over the last years. The prognosis is determined by tumor stage at diagnosis and in locally advanced stages by response to (radio-)chemotherapy followed by radical surgery. Less than a third of patients with esophageal adenocarcinomas completely respond to neoadjuvant therapies which urgently asks for further strategies to improve these rates. Aiming at the tumor microenvironment with novel targeted therapies can be one strategy to achieve this goal. This review connects experimental, translational, and clinical findings on each component of the esophageal cancer tumor microenvironment involving tumor angiogenesis, tumor-infiltrating immune cells, such as macrophages, T-cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts. The review evaluates the current state of already approved concepts and depicts novel potentially targetable pathways related to esophageal cancer tumor microenvironment.
Keyphrases
- locally advanced
- rectal cancer
- squamous cell carcinoma
- neoadjuvant chemotherapy
- radiation therapy
- induced apoptosis
- phase ii study
- minimally invasive
- cell cycle arrest
- oxidative stress
- cell death
- acute coronary syndrome
- clinical trial
- signaling pathway
- young adults
- coronary artery disease
- cell proliferation
- extracellular matrix
- atrial fibrillation
- squamous cell
- surgical site infection
- drug administration